Abstract
Cancer cells, as with most mammalian cells, depend on a continuous supply of glucose; not only as a precursor of glycoproteins, triglycerides and glycogen, but also as an important source of energy. This review concentrates on GLUT transporter expression in both normal and cancerous classical sex-steroid hormone tissues (i.e. breast, uterus, ovary, testis and prostate, among others). Given the importance of estrogen, progesterone and androgens in carcinogenesis, as well as in survival and propagation of these cancers, this review also highlights the current literature on hormone regulation of glucose transporters and on the role of hypoxia in their expression. Furthermore, the recent explosion of information on the newer GLUT6-12 family members, a brief overview on their function and general expression has been included. Finally, an insight into the use of glucose transporters as markers of cancer progression and clinical outcome is also discussed.
Keywords: GLUT, estrogen, progesterone, testosterone, androgen, fructose, uterus, ovary, breast, prostate
Current Vascular Pharmacology
Title: Glucose Transporters in Sex Steroid Hormone Related Cancer
Volume: 7 Issue: 4
Author(s): Francisco Nualart, Maria de los Angeles Garcia, Rodolfo A. Medina and Gareth I. Owen
Affiliation:
Keywords: GLUT, estrogen, progesterone, testosterone, androgen, fructose, uterus, ovary, breast, prostate
Abstract: Cancer cells, as with most mammalian cells, depend on a continuous supply of glucose; not only as a precursor of glycoproteins, triglycerides and glycogen, but also as an important source of energy. This review concentrates on GLUT transporter expression in both normal and cancerous classical sex-steroid hormone tissues (i.e. breast, uterus, ovary, testis and prostate, among others). Given the importance of estrogen, progesterone and androgens in carcinogenesis, as well as in survival and propagation of these cancers, this review also highlights the current literature on hormone regulation of glucose transporters and on the role of hypoxia in their expression. Furthermore, the recent explosion of information on the newer GLUT6-12 family members, a brief overview on their function and general expression has been included. Finally, an insight into the use of glucose transporters as markers of cancer progression and clinical outcome is also discussed.
Export Options
About this article
Cite this article as:
Nualart Francisco, Garcia de los Angeles Maria, Medina A. Rodolfo and Owen I. Gareth, Glucose Transporters in Sex Steroid Hormone Related Cancer, Current Vascular Pharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157016109789043928
DOI https://dx.doi.org/10.2174/157016109789043928 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Analysis of the Differences in the Expression of mRNAs and miRNAs Associated with Drug Resistance in Endometrial Cancer Cells Treated with Salinomycin
Current Pharmaceutical Biotechnology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science The Emerging Role of Aromatase Inhibitors in the Adjuvant Management of Breast Cancer
Reviews on Recent Clinical Trials Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design Targeting Ovarian Cancer-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Advances in Quantitative Mass Spectrometry Analysis: Weighing in on Isotope Coding and Label-Free Approaches for Expression and Functional Proteomics
Current Analytical Chemistry Epidemiology of Vitamin D and Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma
Combinatorial Chemistry & High Throughput Screening Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Current Molecular Medicine Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets Estrogen-Related Receptors as Emerging Targets in Cancer and Metabolic Disorders
Current Topics in Medicinal Chemistry Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Editorial A New Year of Excellence
Current Molecular Medicine Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets